Bayer for ProfessionalsYour Resource Portal

Resources

HCC Resources

Here you will find relevant materials related to Nexavar® (sorafenib) and Stivarga® (regorafenib) in HCC, as well as links to relevant articles and publications.

National Institute for Health and Care Excellence (NICE) guidance. Sorafenib for treating advanced hepatocellular carcinoma.

Download PDF

National Institute for Health and Care Excellence (NICE) guidance. Regorafenib for previously treated advanced hepatocellular carcinoma.

Download PDF

Scottish Medicines Consortium. Detailed advice on regorafenib 40mg film-coated tablets (Stivarga). SMC No 1316/18.

Download PDF

European Association for the Study of the Liver (EASL) Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Download PDF

Nexavar Prescribing Information

Stivarga Prescribing Information

HCC Guidelines

Nexavar (sorafenib)

Stivarga (regorafenib)

PP-NEX-GB-0217, February 2024

Nexavar® (sorafenib) & Stivarga® (regorafenib)

In HCC

Nexavar Prescribing Information

Stivarga Prescribing Information

PP-NEX-GB-0211, February 2024

Tyrosine Kinase Inhibitors (TKI) Events & Webinars

PP-PF-ONC-GB-0412, February 2024

PP-NEX-GB-0215 | February 2024

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.